Geode Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Geode Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$42.4M	Buy	2,961,186 +33,118	+1%	+$570K	﹤0.01%	1685
2026 Q2	$54.6M	Buy	2,928,068 +149,837	+5%	+$2.18M	﹤0.01%	1575
2026 Q1	$33.2M	Buy	2,778,231 +365,346	+15%	+$4.09M	﹤0.01%	1721
2025 Q4	$30.2M	Buy	2,412,885 +191,959	+9%	+$2.22M	﹤0.01%	1784
2025 Q3	$20.3M	Buy	2,220,926 +434,081	+24%	+$3.26M	﹤0.01%	1993
2025 Q2	$9.8M	Buy	1,786,845 +171,980	+11%	+$1.07M	﹤0.01%	2383
2025 Q1	$10.2M	Buy	1,614,865 +315,543	+24%	+$1.51M	﹤0.01%	2285
2024 Q4	$5.35M	Buy	1,299,322 +35,156	+3%	+$113K	﹤0.01%	2717
2024 Q3	$4.22M	Buy	1,264,166 +117,418	+10%	+$349K	﹤0.01%	2848
2024 Q2	$3.42M	Buy	1,146,748 +248,783	+28%	+$691K	﹤0.01%	2925
2024 Q1	$3.1M	Buy	897,965 +48,084	+6%	+$107K	﹤0.01%	2935
2023 Q4	$1.14M	Buy	849,881 +62,241	+8%	+$94.2K	﹤0.01%	3306
2023 Q3	$1.72M	Buy	787,640 +8,819	+1%	+$19.9K	﹤0.01%	3123
2023 Q2	$1.86M	Buy	778,821 +530,528	+214%	+$1.34M	﹤0.01%	3134
2023 Q1	$459K	Buy	248,293 +36,746	+17%	+$83.1K	﹤0.01%	3673
2022 Q4	$408K	Buy	211,547 +11,326	+6%	+$22.3K	﹤0.01%	3764
2022 Q3	$308K	Buy	200,221 +5,075	+3%	+$16.6K	﹤0.01%	3972
2022 Q2	$548K	Buy	195,146 +122,402	+168%	+$301K	﹤0.01%	3711
2022 Q1	$160K	Buy	72,744 +23,667	+48%	+$24.5K	﹤0.01%	4478
2021 Q4	$38K	Hold	49,077	–	–	﹤0.01%	4896
2021 Q3	$67K	Hold	49,077	–	–	﹤0.01%	4749
2021 Q2	$110K	Hold	49,077	–	–	﹤0.01%	4536
2021 Q1	$133K	Hold	49,077	–	–	﹤0.01%	4233
2020 Q4	$118K	Hold	49,077	–	–	﹤0.01%	4024
2020 Q3	$197K	Buy	49,077 +7,164	+17%	+$33.7K	﹤0.01%	3728
2020 Q2	$275K	Hold	41,913	–	–	﹤0.01%	3570
2020 Q1	$137K	Buy	41,913 +431	+1%	+$1.96K	﹤0.01%	3660
2019 Q4	$155K	Hold	41,482	–	–	﹤0.01%	3882
2019 Q3	$186K	Hold	41,482	–	–	﹤0.01%	3798
2019 Q2	$311K	Buy	+41,482	New	+$357K	﹤0.01%	3637

Other funds holding TRVI

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Peregrine Capital Management Minneapolis, Minnesota $2.95B AUM 28.43% 1-Year Est. Return

Geode Capital Management's TRVI Position: Q3 2026 in Review

Geode Capital Management increased its Trevi Therapeutics (TRVI) stake by 1.1% in Q3 2026, buying an estimated $570K and bringing the position to 2,961,186 shares worth $42.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1685.

Geode Capital Management first reported a position in TRVI in Q2 2019 and has held it in 30 quarters since. The position peaked at $54.6M in Q2 2026. 71 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.

Geode Capital Management held 2,961,186 shares of Trevi Therapeutics worth $42.4M as of Q3 2026.
Geode Capital Management bought 33,118 Trevi Therapeutics shares in Q3 2026, an estimated $570K.
Trevi Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #1685 holding.
Geode Capital Management first reported a position in Trevi Therapeutics in Q2 2019 and has held it in 30 quarters since.
Geode Capital Management's Trevi Therapeutics position peaked at $54.6M in Q2 2026.
71 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.